Mercury Pharmaceuticals

MC-CV100 is an inhaled, targeting the SARS-CoV-2 viral genome for the potential treatment and/or prevention of COVID-19.

MC-D101 is a biologic entity being studied for the treatment of cardiovascular disease.

MC-C852 is a chemical entity being studied for the treatment of cancer.

MC-T176 is a large molecule being studied for the treatment of autoimmune diseases.

Unique, disease modifier mechanism of action to prevent and treat mucositis caused by cancer therapy. Strong preclinical evidence that supports the MoA.

Validated and safe API for the treatment of atopic dermatitis and psoriasis using an innovative topical formulation. Clinical PoC results by 2027.

Injectable product with strong nephroprotective activity in animal models. Clinical PoC by 2027.

Herb extract: An allergoid preparation of grass pollen extract for subcutaneous injection.

MC-H19016 aims to treat hemophilia and rare bleeding disorders for subcutaneous injection.

MC-H19018 is a subcutaneously administered, investigational RNAi therapeutic targeting proprotein convertase subtilisin kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia.

MC-H19021 is a subcutaneously administered, investigational RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of chronic HBV infection by our collaborators at Vir Biotechnology. ALN-HBV02 is designed to inhibit expression of all HBV proteins, including hepatitis B surface antigen (HBsAg).

MC-0P-23908 aims to repair the mutation in the eye, leading to normal ABCA4 protein which will potentially stop and perhaps reverse the progression of the disease.

MC-K326 aims to treat non-alcoholic steatohepatitis (NASH) for subcutaneous injection.

Clinical stage product with proven safety repositioned to treat aortic aneurism. Very solid preclinical evidence. Clinical PoC in Marfan syndrome patients by 2027

Clinical stage product with proven safety repositioned to treat complement-mediated diseases for subcutaneous injection.

Immunomodulatory naturally occurring blood-protein that induces tolerogenesis in dendritic cells, to treat rheumatoid arthritis, lupus nephritis, IBD and other autoimmune diseases. Preclinical candidate ready to start regulatory development

Peptide with novel, targeted immunomodulatory mechanism of action, superior safety profile over current biologics, and displaying a low manufacturing cost. In vivo evidence in IBD animal model. MC-K341 targets SAA and IL1β. Next relevant value milestone:

Human naturally occurring protein that increases survival and ameliorates behavior and histochemical readouts. Preclinical PoC in ALS model in 2013.

OBJECT

Previous results showed that, after intraperitoneal administration of 50 ng of MC-K330-01 to no symptomatic mSOD1G93A mice, treated animals resulted in increased survival, delayed onset of disease and improved the general state.

In the current project, it is proposed to study the effect of MC-K330-01 when administered to symptomatic SOD1G93A mice in early stages of illness (from day 50, subcutaneous administration, 3 times per week).

CONCLUSIONS

Therapeutic potential of the compound was evaluated in SOD1G93A ALS mouse model. The drug was delivered subcutaneously in postnatal day 50 female/male mice. Behavioral tests (rotarod, catwalk gait and open field analysis system), electromyography, onset of disease, mouse survival, immunohistochemical, histological and NMJ analysis were used to evaluate the effect of treatment in the ALS model.

Marginal but not significant efficacy of tested compound was observed with Catwalk gait analysis and NMJ pathology. Other parameters showed no significant effects of the treatment in SOD1G93A.